AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 9, 2019

Primary Completion Date

February 25, 2020

Study Completion Date

March 4, 2020

Conditions
Healthy
Interventions
DRUG

AX-8 Part 1

5, 10, 20, and 40 mg AX-8 orally disintegrating tablets (ODTs), up to 80 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved on the back of the tongue while the subject is in a sitting position. The subjects will be instructed not to suck, chew or swallow the tablet, i.e. to allow it to dissolve on the back of the tongue without any further intervention.

DRUG

AX-8 Part 2

5 and 40 mg AX-8 orally disintegrating tablets (ODTs), 45 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved in the mouth while the subject is in a sitting position. The subjects will be instructed to actively move the tablet around in their mouth (i.e. active oral manipulation of the tablet) until it is fully dissolved.

Trial Locations (1)

M23 9QZ

Medicines Evaluation Unit (MEU) Ltd, Manchester

All Listed Sponsors
lead

Axalbion SA

INDUSTRY

NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects | Biotech Hunter | Biotech Hunter